Combination Immunotherapy with a Dendritic Cell based p53 Vaccine (Ad-p53 DCV) plus Ipilimumab and Nivolumab

This investigator initiated trial is being conducted to evaluate the safety and efficacy of an experimental immunotherapy treatment using the adenoviral p53 dendritic cell vaccine (Ad-p53 DCV) in combination with Nivolumab and Ipilimumab.

Click link for more info